New product: Pemazyre (pemigatinib) 4.5 mg, 9mg and 13.5mg - tablets

This kinase inhibitor of FGFR1, 2 and 3 is licensed as monotherapy for treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after ≥1prior line of systemic therapy

Source:

electronic Medicines compendium